Enterprise Value

82.22M

Cash

31.51M

Avg Qtr Burn

-18.75M

Short % of Float

5.48%

Insider Ownership

9.73%

Institutional Own.

29.87%

Qtr Updated

12/31/22


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Klisyri (Tirbanibulin ointment) Details
Skin disease/disorder, Actinic keratosis

Approved

Quarterly sales

Oral paclitaxel + encequidar Details
Metastatic breast cancer, Cancer, Solid tumor/s

NDA

FDA meeting

Phase 2

Data readout

Phase 2

Update

Oral Paclitaxel + KEYTRUDA (Pembrolizumab) Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s

Phase 1/2

Update

Phase 1b

Data readout

KUR-501 Details
Neuroblastoma

Phase 1

Data readout

KUR-502 Details
B-cell malignancies

Phase 1

Update

Failed

Discontinued

Failed

Discontinued

Oral docetaxel + encequidar Details
Solid tumor/s, Cancer, Prostate cancer

Failed

Discontinued